5,290
Participants
Start Date
April 30, 1990
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Memorial Sloan Kettering Cancer Center, New York
Collaborators (21)
Rockefeller University
OTHER
Flinders Medical Centre
OTHER_GOV
University of Southern California
OTHER
Gen-Probe, Incorporated
INDUSTRY
Genentech, Inc.
INDUSTRY
General Electric
INDUSTRY
Purdue University
OTHER
Biocept, Inc.
INDUSTRY
Duke University
OTHER
Ikonysis
INDUSTRY
Array Genomics
INDUSTRY
Cold Spring Harbor Laboratory
OTHER
Nodality
INDUSTRY
Epic Sciences
INDUSTRY
Rutgers Cancer Institute of New Jersey
OTHER
Dana-Farber Cancer Institute
OTHER
Johns Hopkins University
OTHER
M.D. Anderson Cancer Center
OTHER
Oregon Health and Science University
OTHER
University of California, San Francisco
OTHER
University of Chicago
OTHER
University of Michigan
OTHER
University of Washington
OTHER
University of Wisconsin, Madison
OTHER
Fred Hutchinson Cancer Center
OTHER
Broad Institute of MIT and Harvard
OTHER
Weill Medical College of Cornell University
OTHER
Institute of Cancer Research, United Kingdom
OTHER
Vitatex Inc.
INDUSTRY
Serametrix Corporation
INDUSTRY
Promega Corporation
INDUSTRY
Creatv Microtech, Inc.
OTHER
Viatar LLC
INDUSTRY
Massachusetts Institute of Technology
OTHER
Advanced Cell Diagnostics
INDUSTRY
ApoCell, Inc.
INDUSTRY
Beckman Coulter GmbH
INDUSTRY
Bioview, Inc.
INDUSTRY
Clearbridge BioMedics Pte Ltd., Singapore
INDUSTRY
Cynvenio Biosystems
INDUSTRY
Exosome Diagnostics, Inc.
INDUSTRY
Fluxion Biosciences
INDUSTRY
Foundation Medicine
INDUSTRY
Universitätsklinikum Hamburg-Eppendorf
OTHER
Brooklyn ImmunoTherapeutics, LLC
INDUSTRY
Ohio State University
OTHER
Palo Alto Research Center
OTHER
Rarecells
INDUSTRY
Silicon Biosystems
INDUSTRY
The Scripps Research Institute
OTHER
University of Minnesota
OTHER
Janssen Diagnostics, LLC
INDUSTRY
University of Regensburg
OTHER
Innocrin Pharmaceuticals Inc.
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER